Načítá se...
Opportunities and challenges for antisense oligonucleotide therapies
Antisense oligonucleotide (AON) therapies involve short strands of modified nucleotides that target RNA in a sequence‐specific manner, inducing targeted protein knockdown or restoration. Currently, 10 AON therapies have been approved in the United States and Europe. Nucleotides are chemically modifi...
Uloženo v:
| Vydáno v: | J Inherit Metab Dis |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891411/ https://ncbi.nlm.nih.gov/pubmed/32391605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jimd.12251 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|